PE20060458A1 - Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm y procedimiento para su preparacion - Google Patents

Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm y procedimiento para su preparacion

Info

Publication number
PE20060458A1
PE20060458A1 PE2005000688A PE2005000688A PE20060458A1 PE 20060458 A1 PE20060458 A1 PE 20060458A1 PE 2005000688 A PE2005000688 A PE 2005000688A PE 2005000688 A PE2005000688 A PE 2005000688A PE 20060458 A1 PE20060458 A1 PE 20060458A1
Authority
PE
Peru
Prior art keywords
mpm
tetrahydroisoquinoline
tetrahydroisoquinolins
inhibitors
substituted
Prior art date
Application number
PE2005000688A
Other languages
English (en)
Inventor
Armin Hofmeister
Manfred Schudok
Hans Matter
Antonio Ugolini
Kristin Breitschopf
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PE20060458A1 publication Critical patent/PE20060458A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE TETRAHIDROISOQUINOLINA DE FORMULA I, DONDE R1, R2 Y R3 SON H, F, NO2, ENTRE OTROS; A ES C(O)R5 O CH2SH; R5 ES OR6, NR6R7 O NR6OH; R6 Y R7 SON H, ALQUILO C1-C6; n ES 0, 1 O 2; L ES O, NR14, ENTRE OTROS; R14 ES H O ALQUILO C1-C6; q ES 1, 2, 3 O 4; R4 ES FENILO O HETEROARILO DE 5 A 14 MIEMBROS, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-(6-FENOXIPIRIDINA-3-SULFONIL)-1,2,3,4-TETRAHIDROISOQUINOLINA-1-HIDROXICARBAMIDA, 2-(6-MORFOLIN-4-ILPIRIDA-3-SULFONIL)-1,2,3,4-TETRAHIDROISOQUINOLINA-1-HIDROXICARBAMIDA, 2-(2-BIFENIL-4-ILETANOSULFONIL)-1,2,3,4-TETRAHIDROISOQUINOLINA-1-HIDROXICARBAMIDA, ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE TRASTORNOS EN CUYO PROGRESO ESTA IMPLICADA UNA ACTIVIDAD REFORZADA DE LAS METALOPROTEINASAS DE LA MATRIZ (MPM)
PE2005000688A 2004-06-30 2005-06-16 Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm y procedimiento para su preparacion PE20060458A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004031850A DE102004031850A1 (de) 2004-06-30 2004-06-30 Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament

Publications (1)

Publication Number Publication Date
PE20060458A1 true PE20060458A1 (es) 2006-05-29

Family

ID=34971773

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000688A PE20060458A1 (es) 2004-06-30 2005-06-16 Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm y procedimiento para su preparacion

Country Status (15)

Country Link
US (1) US20070203118A1 (es)
EP (1) EP1763516A2 (es)
JP (1) JP2008504315A (es)
KR (1) KR20070026679A (es)
CN (1) CN101006059A (es)
AU (1) AU2005259633A1 (es)
BR (1) BRPI0511323A (es)
CA (1) CA2572125A1 (es)
DE (1) DE102004031850A1 (es)
IL (1) IL179974A0 (es)
MX (1) MXPA06014366A (es)
PE (1) PE20060458A1 (es)
TW (1) TW200612940A (es)
UY (1) UY28993A1 (es)
WO (1) WO2006002763A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln
DE102005015040A1 (de) * 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
GB0706072D0 (en) * 2007-03-28 2007-05-09 Sterix Ltd Compound
BR112017018755B1 (pt) * 2015-03-02 2023-05-02 Amgen Inc Compostos bicíclicos de cetona sulfonamida e composição farmacêutica relacionada
US10597378B2 (en) 2017-09-08 2020-03-24 National Health Research Institutes Tetrahydroisoquinolines for use as MOR/NOP dual agonists
TWI650313B (zh) * 2017-09-08 2019-02-11 財團法人國家衛生研究院 雜環化合物及其用途
CN110835639B (zh) * 2018-08-16 2021-08-10 苏州同力生物医药有限公司 一种制备(s)-1,2,3,4-四氢异喹啉-1-甲酸及其衍生物的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19542189A1 (de) * 1995-11-13 1997-05-15 Hoechst Ag Cyclische N-substituierte alpha-Iminohydroxamsäuren
ATE213232T1 (de) * 1995-11-13 2002-02-15 Hoechst Ag Cyclische und heterocyclische n-substituierte alpha-iminohydroxam- und carbonsäuren
US6770647B2 (en) * 2001-08-17 2004-08-03 Bristol-Myers Squibb Pharma Company Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
DE10344936A1 (de) * 2003-09-27 2005-04-21 Aventis Pharma Gmbh Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
US7205315B2 (en) * 2003-09-27 2007-04-17 Sanofi-Aventis Deutschland Gmbh Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases

Also Published As

Publication number Publication date
US20070203118A1 (en) 2007-08-30
CA2572125A1 (en) 2006-01-12
JP2008504315A (ja) 2008-02-14
DE102004031850A1 (de) 2006-01-26
TW200612940A (en) 2006-05-01
EP1763516A2 (de) 2007-03-21
MXPA06014366A (es) 2007-03-08
WO2006002763A3 (de) 2006-03-16
WO2006002763A2 (de) 2006-01-12
KR20070026679A (ko) 2007-03-08
BRPI0511323A (pt) 2007-12-04
CN101006059A (zh) 2007-07-25
UY28993A1 (es) 2006-01-31
IL179974A0 (en) 2007-05-15
AU2005259633A1 (en) 2006-01-12

Similar Documents

Publication Publication Date Title
PE20060458A1 (es) Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm y procedimiento para su preparacion
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY27774A1 (es) Inhibidores de metaloproteinas de triaril-oxi-aril-espiropirimidina-2,4,6-triona
AR036684A1 (es) Inhibidores de glicogeno sintasa quinasa-3(gsk-3) para tratar glaucoma
EA200601239A1 (ru) Замещённые хинолиновые соединения
ECSP066886A (es) Compuestos y métodos para el tratamiento de dislipidemia
ES2282685T3 (es) Derivados de hidroxietilamina para el tratamiento de la enfermedad de alzheimer.
PE20091092A1 (es) Compuestos heterociclicos como inhibidores de la via hedgehog
DOP2004000888A (es) 2-hidroxi-3-diaminoalcanos de benzamida (benzamide 2-hydroxy-3-diaminoalkanes
EA200601358A1 (ru) Новые ингибиторы химазы
CY1107817T1 (el) Καρβοξαμιδια θειοφαινιου ως αναστολεις του ενζυμου ικκ-2
AR041298A1 (es) Derivados de pirrolidona como inhibidores de maob
PE20071132A1 (es) Compuestos macrociclicos como inhibidores del factor viia
PE20060355A1 (es) TIENO[3,2-b]PIRIDIN-6-CARBONITRILOS COMO INHIBIDORES DE LA QUINASA PROTEICA
CR9210A (es) Pderivados de n-(heteroaril)-1h-indol-2-carboxamidas y su utilizacion como ligandos del receptor vaniloide trpv1
EA201070442A1 (ru) НОВЫЕ ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ
NO20054340L (no) Nye sammenkoplede heterocykler og deres anvendelse
EA200600605A1 (ru) Перегруппированные пентанолы, способ их получения и их применение в качестве противовоспалительных средств
HN2003000379A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
NO20050871L (no) 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer
DK1448562T3 (da) Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
DK1723140T3 (da) Fremgangsmåde til fremstilling af tryptase-inhibitorer
AR039664A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan

Legal Events

Date Code Title Description
FA Abandonment or withdrawal